DarioHealth Corp Stock News

DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue gr

DarioHealth Co. NASDAQ: DRIO is an AI-powered digital therapeutics platform and provider that adaptively personalizes monitoring and treatments for chronic diseases. The mobile app manages five common

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Chuck Padala - Managing Director, Investor Relations Erez Raphael - Chief Executive Offic

DarioHealth Corp. (NASDAQ:DRIO ) Q4 2022 Results Conference Call March 9, 2023 8:30 PM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson -

Company to host conference call and webcast at 8:30 am ET NEW YORK , March 2, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today ann

DarioHealth rallied off a low in December and since raced to new highs. Market generated data suggests the rally could extend over the coming weeks to months.

We've revised our rating on DarioHealth to a buy, with consideration to tactical allocation for equity portfolios. DRIO's Q3 numbers came in strong with upsides versus consensus at the top and bottom

DarioHealth Corp. (NASDAQ:DRIO ) Q3 2022 Results Conference Call November 15, 2022 8:30 AM ET Company Participants Glenn Garmont - IR Erez Raphael - CEO Rick Anderson - President Conference Call Parti

U.S. stocks traded higher this morning, with the Dow Jones gaining around 175 points on Wednesday. The Federal Reserve will announce its policy decision at 2:00 p.m. ET. The country’s central bank i

DarioHealth Corp (NASDAQ:DRIO ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Glenn Garmont - LifeSci Advisors Erez Raphael - CEO & Director Richard Anderson - Presi

Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan - Fundamentals: Company positioned to avoid dilutive financing after recent $50M credit facility with OrbiMed - Catalys

Cowen & Co. has decided to maintain its Outperform rating of DarioHealth (NASDAQ:DRIO) and raise its price target from $14.00 to $18.00. Shares of DarioHealth are trading up 5.8% over the last 24 hour

Upgrades B of A Securities upgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE:RBA) from Underperform to Neutral. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.46,

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson -

DarioHealth's (DRIO) CEO Erez Raphael on Q4 2021 Results - Earnings Call Transcript